<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108623</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1306</org_study_id>
    <nct_id>NCT05108623</nct_id>
  </id_info>
  <brief_title>A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1 Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer (iNKT; agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiNK Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agenus Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary&#xD;
      clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants&#xD;
      with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose&#xD;
      (RP2D) in solid tumors. This Phase 1 will also explore the safety, tolerability, and&#xD;
      preliminary clinical activity of agenT-797 in combination with approved immune checkpoint&#xD;
      inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of the AEs by the dose of iNKT cell therapy as a single agent</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-related AEs by the dose of iNKT cell therapy as a single agent</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity grade of AEs according to NCI CTCAE v5.0 by dose of iNKT cell therapy as a single agent</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of DLTs during the first 28 days after administration</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The persistence, or length of time that agenT-797 is present in peripheral blood samples will be measured through collection of Peripheral blood mononuclear cells (PBMCs) and analysis by flow cytometry.</measure>
    <time_frame>Pre-dose, 2 hours after cell infusion and on Days 2, 5, 8, 15, 22, and 29; Weeks 6, 8, and 12; and Months 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) for Solid Tumors per RECIST 1.1 guidelines and Prostate Cancer (not evaluable per RECIST 1.1) per Prostate Cancer Working Group 3</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) for Solid Tumors per RECIST 1.1 guidelines and Prostate Cancer (not evaluable per RECIST 1.1) per Prostate Cancer Working Group 3</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) for Solid Tumors per RECIST 1.1 guidelines and Prostate Cancer (not evaluable per RECIST 1.1) per Prostate Cancer Working Group 3</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Panel reactive antibody (PRA)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Donor Specific Antibody (DSA)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tumor, Solid</condition>
  <arm_group>
    <arm_group_label>Part 1: Monotherapy with agenT-797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single prespecified dose of agenT-797 administered by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: agenT-797 in Combination with approved immune checkpoint inhibitors (ICIs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single prespecified dose of agenT-797 administered by intravenous infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>agenT-797</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Part 1: Monotherapy with agenT-797</arm_group_label>
    <arm_group_label>Part 2: agenT-797 in Combination with approved immune checkpoint inhibitors (ICIs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Approved anti-PD-1</intervention_name>
    <description>(nivolumab, pembrolizumab)</description>
    <arm_group_label>Part 2: agenT-797 in Combination with approved immune checkpoint inhibitors (ICIs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological evidence of relapsed or refractory solid tumor malignancy&#xD;
             for which no standard therapy is available or standard therapy has failed&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as&#xD;
             assessed by local site Investigator/radiology. Lesions situated in a previously&#xD;
             irradiated area are considered measurable if progression has been demonstrated in such&#xD;
             lesions&#xD;
&#xD;
          -  Part 2 only, patients must have progressed per Investigator assessment on&#xD;
             pembrolizumab or nivolumab, and agree and are able to continue on the inhibitor(s)&#xD;
             while on study&#xD;
&#xD;
          -  No other medical, surgical, or psychiatric condition (including active substance&#xD;
             abuse) that would interfere with compliance to the protocol, as determined by the&#xD;
             Principal Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent invasive malignancy&#xD;
&#xD;
          -  Brain and/or leptomeningeal metastases, untreated or require current therapy&#xD;
&#xD;
          -  Prior radiotherapy within 2 weeks of start of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>MiNK Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MiNK Therapeutics Clinical Trial Information</last_name>
    <phone>781-674-4265</phone>
    <email>clinicaltrialinfo@agenusbio.com</email>
  </overall_contact>
  <link>
    <url>https://packageinserts.bms.com/pi/pi_opdivo.pdf</url>
    <description>Nivolumab [Package Insert]. Princeton, NJ: Bristol Myers Squibb Company: 2014.</description>
  </link>
  <link>
    <url>https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf</url>
    <description>Pembrolizumab [Package Insert]. White House Station, NJ: Merck &amp; Co. Inc.; 2014-2021.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>iNKT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

